Regeneron director exercises options and sells shares
REGENERON PHARMACEUTICALS, INC. director Kathryn Guarini exercised 400 non-qualified stock options for Common Stock at an exercise price of $719.37 per share on August 10, 2026, leaving 1,558 options outstanding that expire on January 2, 2035.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
REGENERON PHARMACEUTICALS, INC. director Kathryn Guarini exercised 400 non-qualified stock options for Common Stock at an exercise price of $719.37 per share on August 10, 2026, leaving 1,558 options outstanding that expire on January 2, 2035.
The 400 acquired shares were then sold at $800.00 per share the same day. The disposition and acquisition were made pursuant to a Rule 10b5-1(c) trading plan adopted on February 13, 2026.
Insider Trade Summary 10b5-1
Exercise and Sale: 400 shares ($32K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Guarini Kathryn
Role
Director
Sold
400 shs ($320K)
Approx. gross sale proceeds
$320K
Approx. exercise cost
$288K
Approx. pre-tax spread
$32K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) F1, F2 | 400 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 400 | $719.37 | $288K |
| Sale | Common Stock F1 | 400 | $800.00 | $320K |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 1,558 contracts (Direct);
Common Stock — 603 shares (Direct)
Footnotes (2)
- F1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026.
- F2. On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.
Key Figures
Options exercised: 400 shares
Exercise price: $719.37 per share
Shares sold: 400 shares
+4 more
7 metrics
Options exercised
400 shares
Non-Qualified Stock Options exercised on August 10, 2026
Exercise price
$719.37 per share
Exercise price of Non-Qualified Stock Options for Common Stock
Shares sold
400 shares
Common Stock sale on August 10, 2026 following option exercise
Sale price
$800.00 per share
Price for sale of 400 shares of Common Stock
Options remaining
1,558 options
Non-Qualified Stock Options outstanding after the exercise
Option expiration
January 2, 2035
Expiration date of the Non-Qualified Stock Options
10b5-1 plan adoption date
February 13, 2026
Date the Rule 10b5-1(c) trading plan was adopted
Key Terms
Non-Qualified Stock Option, Rule 10b5-1(c), derivative security
3 terms
Non-Qualified Stock Option financial
"Non-Qualified Stock Option (right to buy)"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
Rule 10b5-1(c) regulatory
"plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026"
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did REGN director Kathryn Guarini report in this Form 4?
Kathryn Guarini exercised 400 stock options for Regeneron Common Stock at $719.37 per share and sold 400 shares at $800.00 per share on August 10, 2026, under a Rule 10b5-1 trading plan.
How many Regeneron (REGN) options did Kathryn Guarini exercise and at what price?
She exercised 400 non-qualified stock options for Regeneron Common Stock at an exercise price of $719.37 per share. These options are part of a grant with remaining options that continue to be exercisable until January 2, 2035.
How many Regeneron (REGN) options does Kathryn Guarini still hold after these transactions?
Following the reported exercise, she holds 1,558 non-qualified stock options to acquire Regeneron Common Stock. These options are scheduled to expire on January 2, 2035, if not exercised earlier.
Were Kathryn Guarini’s Regeneron (REGN) trades under a Rule 10b5-1 plan?
Yes. The Form 4 notes that the disposition and acquisition were made under a plan intended to comply with Rule 10b5-1(c), which was adopted on February 13, 2026, before the August 10, 2026 transactions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates